Insulin Mimetic Actions of Polyphenol Epigallocatechin 3-Gallate
This project will highlight the development of a promising new treatment of insulin resistance and type 2 diabetes resulting in a reduced burden of disease in diabetes and cardiovascular disease in the Australian population. By studying the effects of EGCG on insulin microvascular and metabolic actions in muscle, we will determine the potential of this nutritional agent for preventing insulin resistance and type 2 diabetes and provide insight into its mechanism of action. This project will determine whether EGCG or green tea should be prescribed as a supplement to pre-diabetics. We expect this work to produce data strongly advocating the use of this neutraceutical agent in early phases of diabetes. The outcome of this study has the potential to reduce the dose of prescription medications for treating insulin-resistance and type 2 diabetes (which sometimes have unwanted side-effects), while benefiting from the other health benefits of EGCG. This study will boost the functional food industry in Australia and highlight new treatments for insulin-resistance and type 2 diabetes.
Research Groups
Related Diseases
Staff
Team Leaders
Team Members
- Helena Ng (PhD Student)
External Collaborators
- Dr Michael Quon - National Institutes of Health, USA